Hhlr Advisors LTD. Makes New $819,000 Investment in Gossamer Bio, Inc. $GOSS

Hhlr Advisors LTD. purchased a new stake in Gossamer Bio, Inc. (NASDAQ:GOSS) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 4,974,041 shares of the company’s stock, valued at approximately $819,000.

Other hedge funds also recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock valued at $77,000 after purchasing an additional 43,866 shares during the last quarter. Invesco Ltd. bought a new position in shares of Gossamer Bio in the first quarter valued at $48,000. Cubist Systematic Strategies LLC bought a new position in shares of Gossamer Bio in the first quarter valued at $213,000. Goldman Sachs Group Inc. lifted its position in shares of Gossamer Bio by 720.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after acquiring an additional 825,047 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Gossamer Bio by 5,250.1% during the 1st quarter. Jane Street Group LLC now owns 683,423 shares of the company’s stock valued at $752,000 after acquiring an additional 670,649 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

Shares of NASDAQ:GOSS opened at $0.17 on Thursday. The firm has a 50 day simple moving average of $0.17 and a 200 day simple moving average of $0.43. Gossamer Bio, Inc. has a 52 week low of $0.11 and a 52 week high of $3.87. The company has a market cap of $40.81 million, a PE ratio of -0.25 and a beta of 2.04.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.04. The firm had revenue of $9.24 million for the quarter, compared to analysts’ expectations of $3.63 million. On average, equities analysts predict that Gossamer Bio, Inc. will post -0.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

GOSS has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a report on Monday, July 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gossamer Bio in a research report on Friday, August 14th. Finally, Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price target on the stock in a research note on Tuesday, July 28th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Gossamer Bio currently has a consensus rating of “Hold” and an average price target of $3.20.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.